Rocket Lab USA (NASDAQ: RKLB) delivered a second quarter defined by trajectory, not a single number. Revenue of $234 million beat the $231.6 million consensus by a modest 1%. The 62% year-over-year jump from $144.5 million tells the real story. This company is scaling faster than the market models, and the numbers underneath confirm it.
The headline beat came from product revenue, which surged to $181.3 million from $92.7 million a year ago, a 96% increase. Service revenue held roughly flat at $52.7 million. The mix shift toward products—now 77% of total revenue versus 64% a year ago—reflects the ramp in satellite manufacturing and launch vehicle deliveries. Gross profit rose to $84.6 million from $46.4 million, with GAAP gross margin expanding to 36.1% from 32.1%. On a non-GAAP basis, gross margin hit 41.5%, up from 36.9%, as the company absorbed higher volume without proportionate cost growth.
The operating loss narrowed to $57.5 million from $59.6 million. That understates the improvement. Research and development spending jumped to $82.4 million from $66.1 million, driven by Neutron rocket development and the GHOST launch system. Strip out stock-based compensation and transaction costs, and non-GAAP operating loss improved to $18.7 million from $33.6 million. Adjusted EBITDA loss narrowed to $8.8 million from $27.6 million. The company is burning less cash to generate far more revenue.
The backlog is the most forward-looking metric. At $2.36 billion, it is up 137% year-over-year and represents roughly 10 quarters of revenue at the current run rate. More than $1 billion in new contracts were signed in Q3 alone, including a $397 million U.S. Space Force award for Flatellite spacecraft under the SB-AMTI program. Rocket Lab is one of only two vendors delivering both launch and spacecraft for that program, a structural advantage that competitors without vertical integration cannot replicate quickly.
Management guided Q3 revenue to $250 million to $265 million, implying another sequential record and year-over-year growth of roughly 60% at the midpoint. The guidance range is wide—$15 million—suggesting some uncertainty around launch timing or milestone payments. GAAP gross margin is expected at 29% to 31%, below the Q2 print, while non-GAAP gross margin is guided to 35% to 37%, also a step down. The margin compression in the guide likely reflects mix: more lower-margin launch contracts and satellite production in the near term, with the higher-margin Neutron and constellation revenue still ahead.
The Iridium acquisition announcement is the strategic centerpiece. Rocket Lab is buying a constellation operator, not just building satellites for others. That shifts the business model from contractor to operator, with recurring service revenue and direct end-user relationships. The $2.1 billion cash position at quarter end, bolstered by $1.5 billion in ATM equity proceeds, gives it the balance sheet to execute. But the operating loss and negative free cash flow mean the clock is ticking on demonstrating that the vertical integration thesis produces better unit economics than the sum of its parts.
The Q3 guide implies adjusted EBITDA loss of $17 million to $23 million, wider than the $8.8 million loss in Q2. That is not a deterioration in underlying performance; it reflects the cost of absorbing Mynaric and Motiv acquisitions and continued investment in Neutron and GHOST. The company is trading near-term profitability for long-term positioning. For investors, the question is whether the backlog conversion and margin expansion materialize before the cash burn forces another equity raise.
What to watch next: Neutron's first launch, targeted for Q4 2026, is the single most important catalyst. A successful flight would unlock a medium-lift market that Rocket Lab currently cannot address. The GHOST system's operational debut in Alaska in 2027 is a longer-term driver. And the Iridium deal's closing and integration will determine whether Rocket Lab becomes a tier-1 space power or remains a high-growth contractor with a lot of moving parts.